足细胞特异性Nlrp3炎症小体激活促进糖尿病肾病
糖尿病肾病缺乏有效治疗,无菌性炎症是其标志之一。本研究在髙血糖小鼠中发现,足细胞特异性表达Nlrp3功能获得性突变可加重肾损害,而足细胞特异性Nlrp3或Caspase-1缺失则保护肾脏;Nlrp3缺失完全保护而Caspase-1缺失仅部分保护,且Nlrp3缺失维持了肾小球自噬。
要点
- 足细胞特异性Nlrp3功能获得性突变加重髙血糖小鼠的白蛋白尿、系膜扩张和肾小球基底膜增厚。
- 足细胞特异性Nlrp3缺失对糖尿病肾病完全保护,而Caspase-1缺失仅部分保护。
- 足细胞Nlrp3缺失维持髙血糖小鼠的肾小球自噬,提示其兼有经典和非经典效应。
核心结论
- 足细胞NLRP3炎症小体激活对糖尿病肾病既充分又必要,靶向NLRP3可能是糖尿病肾病有前景的治疗策略。
研究设计与样本
- 在髙血糖小鼠中采用足细胞特异性Nlrp3功能获得性突变(Nlrp3A350V)表达、足细胞特异性Nlrp3缺失及足细胞特异性Caspase-1缺失的动物实验研究。
主要发现
- 足细胞特异性表达Nlrp3A350V的髙血糖小鼠白蛋白尿增加、肾小球系膜扩张和肾小球基底膜厚度加重。
- 足细胞特异性Nlrp3或Caspase-1缺失的髙血糖小鼠对糖尿病肾病有保护作用。
- 足细胞特异性Nlrp3缺失完全保护,而足细胞特异性Caspase-1缺失仅部分保护。
- 足细胞特异性Nlrp3缺失而非Caspase-1缺失维持了髙血糖小鼠的肾小球自噬。
临床怎么用
- 作者认为靶向NLRP3可能是糖尿病肾病有前景的治疗方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Efficient therapies for diabetic kidney disease (DKD), now the leading cause of kidney failure, are lacking. One hallmark of DKD is sterile inflammation (inflammation in absence of microorganisms), but the underlying molecular mechanisms remain poorly understood. The NLRP3 inflammasome (innate immune system receptors and sensors regulating activation of caspase-1) is a mechanism of sterile inflammation known to be activated by metabolic stimuli and reactive metabolites associated with DKD, including inflammasome activation in podocytes. However, whether NLRP3 inflammasome activation in podocytes contributes to sterile inflammation and glomerular damage in DKD remains unknown. Here, we found that kidney damage, as reflected by increased albuminuria, glomerular mesangial expansion and glomerular basement membrane thickness was aggravated in hyperglycemic mice with podocyte-specific expression of an Nlrp3 gain-of-function mutant (Nlrp3A350V). In contrast, hyperglycemic mice with podocyte-specific Nlrp3 or Caspase-1 deficiency showed protection against DKD. Intriguingly, podocyte-specific Nlrp3 deficiency was fully protective, while podocyte-specific caspase-1 deficiency was only partially protective. Podocyte-specific Nlrp3, but not caspase-1 deficiency, maintained glomerular autophagy in hyperglycemic mice, suggesting that podocyte Nlrp3 exerts both canonical and non-canonical effects. Thus, podocyte NLRP3 inflammasome activation is both sufficient and required for DKD and supports the concept that podocytes exert some immune cell-like functions. Hence, as podocyte NLRP3 exerts non-canonical and canonical effects, targeting NLRP3 may be a promising therapeutic approach in DKD.
引用
- Shahzad K, Fatima S, Khawaja H, et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. Kidney Int. 2022. PMID: 35779608. doi:10.1016/j.kint.2022.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。